Fludarabine

Catalog No.S1491 Synonyms: FaraA, Fludarabinum

Fludarabine Chemical Structure

Molecular Weight(MW): 285.23

Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.

Size Price Stock Quantity  
In DMSO USD 126 In stock
USD 97 In stock
USD 310 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 32 Publications

Purity & Quality Control

Choose Selective STAT Inhibitors

Biological Activity

Description Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.
Targets
STAT1 [4]
(Vascular smooth muscle cells)
In vitro

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  MWHGeY5kfGmxbjDBd5NigQ>? M4q5RlIxKM7:TR?= NWj6O|hSOjRiaB?= NGDLT4ZqdmirYnn0d{BmgHC{ZYPzbY9vKG:oIFnEUy=> MUKyOVk1ODdzMh?=
MV-4-11 NUfrOYtWSXCxcITvd4l{KEG|c3H5 NWW2VHpNOi53IN88US=> M{e1WVQ5KGh? NWDDO5FkcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> MX2yOVEyOTV6Mx?=
THP-1 NVPHc2ZzSXCxcITvd4l{KEG|c3H5 NFjrdpIzNjVizszN NX7OfI46PDhiaB?= NH\L[3ZqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> MV6yOVEyOTV6Mx?=
MOLM 13 NID2T4lCeG:ydH;zbZMhSXO|YYm= Ml\4Nk42KM7:TR?= MVq0PEBp NWjXVIhlcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> NGrzNXMzPTFzMUW4Ny=>
KBM3/Bu2506 NVT2e4hYSXCxcITvd4l{KEG|c3H5 NGK0[HAzNjVizszN MVe0PEBp MYfpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= MX2yOVEyOTV6Mx?=
Nalm-6 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXr0UWI{UUN3ME2xPEDPxE1? NYnmcpBlOjVyNkGxNFE>
Reh NWLNRopiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLhWmVnUUN3ME2zNEDPxE1? NWH2TWZWOjVyNkGxNFE>
U2937 NV\MN5N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nlUGlEPTB;MU[g{txO MXSyOVA3OTFyMR?=
Mec-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzFVJZlUUN3MP-8olUxOCEQvF2= MoLjNlUxPjFzMEG=
RPMI-8226 MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DPVWlEPTB;NUCwJO69VQ>? MlrPNlUxPjFzMEG=
Molt-4 M2rtS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDsU29KSzVyPUG4NEDPxE1? M{j6ZVI2ODZzMUCx
Nalm-6-FluR M1jNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvzTWM2OD1{NUCg{txO NX7teJYyOjVyNkGxNFE>
Raji  Mn3vSpVv[3Srb36gRZN{[Xl? M2Dm[|PDqM7:TR?= M{DUVFI1NzR6L{eyJIg> NIXmR4dqdmS3Y3XzJIFk[3WvdXzheIlwdnNib3[gdFU{NCCyNkOgZY5lKHB5M9Mg NHfIdXEzPDl2ME[5OS=>
PBMC MUXGeY5kfGmxbjDBd5NigQ>? MXW1NE8yODBizszN M{S3XlI1KGh? M1r4fGROW09? NEjlT2VqdmirYnn0d{BUXEGWMTDwbI9{eGixconsZZRqd25? NWK4OlY3OjR7MUG4O|I>
MDA-231 NUD0[IRJTnWwY4Tpc44hSXO|YYm= NEDXTHUyODBizszN NXrCW|hIOjRiaB?= NIqzcoNFVVOR M{K0S4Rm[3KnYYPld{BKTE9iZYjwdoV{e2mxbh?= Ml;aNlQ6OTF6N{K=
624.38mel  MoW5SpVv[3Srb36gRZN{[Xl? NIXCVYQ2OCEQvF2= NX7OZoZbOjRiaB?= MnLSSG1UVw>? MXzk[YNz\WG|ZYOgTWRQKGW6cILld5Nqd25? MYiyOFkyOTh5Mh?=
MDA-231 NXjPbGIyTnWwY4Tpc44hSXO|YYm= NFS0VpQ2OC1{MECg{txO MoTGNlQhcA>? MYrEUXNQ NVHoSoRvcW6qaXLpeJMhUUSRIHHjeIl3cXS7IHnu[IVx\W6mZX70cJkhd2ZibWLORUBt\X[nbIO= M1TpelI1QTFzOEey
624.38mel  NVXQ[phOTnWwY4Tpc44hSXO|YYm= NYqwVXFSPTBvMkCwJO69VQ>? MlqyNlQhcA>? NFrQN2JFVVOR MXjpcohq[mm2czDJSG8h[WO2aY\peJkhcW6mZYDlcoRmdnSueTDv[kBuWk6DIHzleoVtew>? NXWyTGw6OjR7MUG4O|I>
HMECs NH7nfYhHfW6ldHnvckBCe3OjeR?= NXO0W5hROTBywrFOwG3DqA>? NFzJcZY{PsLiaB?= MX3pcohq[mm2czDJSm7Pu8LiYX7kJGxRWyCrbnT1Z4VlKFOWQWSxJJBpd3OyaH;yfYxifGmxbjDhcoQhUVKIMTDlfJBz\XO|aX;u MoDENlQzOTF|Mke=
HMECs  M17zdGZ2dmO2aX;uJGF{e2G7 NV;WO2dFOTBywrFOwG3DqA>? M{H1UVM3yqCq MXvpcohq[mm2czDJSm7PucLibXXkbYF1\WRicHjvd5Bpd3K7bHH0bY9vKG:oIGPURXQyKGGwZDDTWGFVOyxiYoX0JI5wfCCxZjDTWGFVOg>? NIDpeJYzPDJzMUOyOy=>
BJAB NVe4[m5XSXCxcITvd4l{KEG|c3H5 M3zi[|XDqM7:TR?= MUGyOEBp NHTzcIhqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MlTkNlQxPTdzNEe=
I-83 NVHzb5lkSXCxcITvd4l{KEG|c3H5 M2rhVVXDqM7:TR?= NIPodFUzPCCq M2XpeIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NUfkXnM3OjRyNUexOFc>
NALM6 MVfBdI9xfG:|aYOgRZN{[Xl? MUK1xsDPxE1? NELLT2YzPCCq M1TlR4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NXvhXndHOjRyNUexOFc>
DU-145 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3QNE0yOCEQvHevcYw> M4HSPFQ5KGkEoB?= MorWbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NH\Uc5UzOzd|NEixOS=>
Nalm-6 NEfXT5ZHfW6ldHnvckBCe3OjeR?= NEi0SIMyOMLizszN MXSxM|IwPCCq MX;pcoR2[2W|IHH1eI9xcGGpeR?= MmTVNlM3QDF{MkO=
Reh M2HkUWZ2dmO2aX;uJGF{e2G7 MmrJNVDDqM7:TR?= NFnVeG0yNzJxNDDo MoDFbY5lfWOnczDheZRweGijZ4m= NX\BU25UOjN4OEGyNlM>
Nalm-6 NEjhWZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxKOLKvEGw5qCK|ryP NXjncXhlOjN4OEGyNlM>
Reh NVnPUYxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfOTodKSzVyIPMIwFEx6oDLzszN NWTxWI9TOjN4OEGyNlM>
HEC1A M33MWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKxNFAuPTByIN88US=> NYmyPINKOjRiaB?= NITrPG1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXmyN|U6PTZ7Nx?=
AN3CA MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXOxNFAuPTByIN88US=> NEHyTHAzPCCq NYrE[m9kcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NF[y[JEzOzV7NU[5Oy=>
HEC50B MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojONVAxNTVyMDFOwG0> MlvCNlQhcA>? MXLpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> MW[yN|U6PTZ7Nx?=
HEC1A MoPsRZBweHSxc3nzJGF{e2G7 NH;EWYIzOC9zMECg{txO MVKyOEBp Ml;VbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NUWxUWNUOjN3OUW2PVc>
AN3CA MV\BdI9xfG:|aYOgRZN{[Xl? NHrySFQzOC9zMECg{txO MWCyOEBp NXO4OHd2cW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1raW|I{PTl3Nkm3
HEC50B NX6zW5NJSXCxcITvd4l{KEG|c3H5 MnfnNlAwOTByIN88US=> Mk\xNlQhcA>? MWHpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NXy3UJlxOjN3OUW2PVc>
EHEB NHvUcnBCeG:ydH;zbZMhSXO|YYm= MYe0NEDPxE1? MoTyNlQhcA>? MV3pcoR2[2W|IHHwc5B1d3Orcx?= NUL3bFRVOjN2OUewO|U>
A549 NUDOSFF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELQ[FhKSzVyPUG1MlfDuTJwODFCuW0> NHfGSHYzOzN5N{G5Ni=>
A549 GAPDH-deficient NXfWdoo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf5SWJ{UUN3ME2xPE42yrF{LkOgxtVO M{nTeVI{Ozd5MUmy
CLL  MUDBdI9xfG:|aYOgRZN{[Xl? NH64O4MyOCEQvF5CpC=> MlPiNlQuQTZiaB?= MVHpcoR2[2W|IHHwc5B1d3SrYzDj[YxtKGSnYYTo Mn7ENlIzODd4OE[=
MEC1 Mn33RZBweHSxc3nzJGF{e2G7 NVjuRXZoOTBywrFOwG0> MmPIO|IhcA>? M4WzeIlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? M4DXOFIzOTN{OUez
U937  M{j1UmFxd3C2b4Ppd{BCe3OjeR?= MoLTNE45KM7:TR?= NGjk[WI1NTR6IHi= NX7lVXVYcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> NFPLT4wzOjB5NEewNC=>
U937  NWO2NIVMSXCxcITvd4l{KEG|c3H5 MnL6NUDPxE1? NV7JeY4xQTZiaB?= M1X5U4lv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 MX:yNlAzOzV{Mx?=
Daudi MY\BdI9xfG:|aYOgRZN{[Xl? MlfMNlAh|ryP NF3Ec|A6PiCq M{mxWIlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 MUeyNlAzOzV{Mx?=
J45.01 MWjBdI9xfG:|aYOgRZN{[Xl? NGLrRZoyKM7:TR?= MmLJPVYhcA>? MnW5bY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= MUeyNlAzOzV{Mx?=
RPMI 8226 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJ3LkpCpOKyyqB|Lkeg{txO NHLUUnkzOTl2OEK2OC=>
CEM NITSPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\0T5NKSzVyPUKuOOKhyrIEoECuOEDPxE1? MV:yNVk1QDJ4NB?=
Raji M2fMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\SdWlKSzVyPUCuOFfDqMLzwrCwMlA1KM7:TR?= NFXidFYzOTl2OEK2OC=>
U937 MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2e1cWlEPTB;MD6yOOKhyrIEoECuNFQh|ryP NXnDfmk6OjF7NEiyOlQ>
K562 NGroNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTBXXFKSzVyPUCuOFTDqMLzwrCwMlA2KM7:TR?= MX2yNVk1QDJ4NB?=
NALM-6 MXzBdI9xfG:|aYOgRZN{[Xl? NUS2S2NwOTBizszNxsA> MmHUNlQhcA>? M2n5ZYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3zp[4h1dHl? M1HUfFIyPjl7M{iz
JMV-3 M3;tXmFxd3C2b4Ppd{BCe3OjeR?= MX[xNEDPxE4EoB?= MXSyOEBp NWi5fIhtcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzcIlocHSueR?= NXPtelV5OjF4OUmzPFM>
EHEB M1nxc2Z2dmO2aX;uJGF{e2G7 NX3tNZpRPS13MDFOwG0> MWeyOEBp NFrmfZRl\WO{ZXHz[ZMheDJzIHX4dJJme3Orb36gd4lodmmoaXPhcpRtgQ>? M2G3Z|IyOTZ6M{mx
JVM-2  NWntUGx3TnWwY4Tpc44hSXO|YYm= NIrtemQ{OCEQvF2= MorwNlQhcA>? NWHlbHVn\GWlcnXhd4V{KHB{MTDlfJBz\XO|aX;u NVHmcng4OjFzNkizPVE>
KBM3/Bu2506 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[4UWlEOjB;MD62O{DDvU1? M{DHe|IxQTN|NUC5
KBM3/Bu2506 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33RclAvPiEQvF2= MYCyOEBp NFzURXRqdmO{ZXHz[ZMhfGinIHPlcIwh\nKjY4Tpc44hcW5iUz3wbIF{\Q>? M3\OblIxQTN|NUC5
MDA-MB-231 MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrXNWxlUUN3ME20MlAh|ryP MXeyNFQ1PzN7MB?=
MCF-7 NUDvZZZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHFTWM2OD1zNT6wJO69VQ>? M{Tz[|IxPDR5M{mw
HLE-B3  MVvGeY5kfGmxbjDBd5NigQ>? M3T1dFI2KM7:TR?= NFXoTWM1QCCq M{TuXYJtd2OtczDJSm4u|rQkgKPpcoR2[2WmIGPURXQyKHCqb4PwbI9zgWyjdHnvckBidmRiSVTPJIV5eHKnc4Ppc44> MXiyNFQ{PTF3OB?=
K562 NYLvfHlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPmO|IhcA>? MoHYTWM2OD1|LkOgcm0> MX6yNFMxPzF7OB?=
BW-225 M{L4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\UdHNQUUN{ME2xMlM4KMPZMUFijLI5yqEQvF5CpC=> M{nt[lE5PjZzM{iw
OH-65 NF3JUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvtTWMzOD1zLkO3JOOYOTEkiKK4xsDPxE4EoB?= NV63W|R3OTh4NkGzPFA>
GR-145 NXqzO|JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXyzcVZyUUN{ME2yMlc1KMPZIEGw5qiTQCBizszNxsA> NGf3VY4yQDZ4MUO4NC=>
A549 M2\JbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzQTWMzOD13LkS4JOOYKDFy4pkSPEDPxE4EoB?= MVexPFY3OTN6MB?=
CaSki  M2P3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7w[YZMUUN{ME2xMlM4KMPZIEGw5qiTPyEQvF5CpC=> NYqzZXRKOTh4NkGzPFA>
ZMK-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PWcGlEOjB;MT6zO{DEnyBzMPMIllYh|ryPwrC= M1vFW|E5PjZzM{iw
SKW6.4 Mn22RZBweHSxc3nzJGF{e2G7 NFnQSVMxNjBzLUGwJO69VQ>? NYraVHF5OjRxNEigbC=> MVPpcoR2[2W|IHPlcIwh\GWjdHigbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? NIraeZgyQDB7MkO0NC=>
RPMI 8226 MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HWT|I1KGh? NHe1XFRKSzVyPUGuOVTDqM7:TR?= MYCxO|k4PjF6Nh?=
MM.1S NILGSWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnuyOFghcA>? Mnf3TWM2OD1zMz60POKh|ryP NIXad4syPzl5NkG4Oi=>
MM.1R MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGW1VZY1QCCq MVvJR|UxRTN|Lke5JO69VQ>? MlnPNVc6PzZzOE[=
U937 M1:yOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnTTVdKSzVyPUOsNlAxKMLzIEW2NEBvVQ>? M374flE2QTNyM{[x

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
procaspase-9 / procaspase-3; 

PubMed: 27223263     


Procaspase-9 and procaspase-3 were analyzed by Western blot in CLL cells from three patients after a 48 h-incubation in the absence or presence of 3 μM aphidicolin (APC) with or without fludarabine at 0.3 and 1 μM. β-Actin served as a loading control.

p-p53 / p53; 

PubMed: 27223263     


(A–B) CLL cells from 3 different patients were incubated for 24 h with fludarabine at the indicated concentrations in the absence or presence of 3 μM aphidicolin (APC). Phosphorylation of p53 at Ser-15 and total p53 were analyzed by Western blot. Data sho䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒

STAT1; 

PubMed: 26677135     


Representative western blot analysis of STAT1 in RAW 264.7 cells treated with STAT1 inhibitor fludarabine (Flu) for 24 h.

27223263 26677135
Immunofluorescence
α-SMA / Vimentin; 

PubMed: 28322315     


FLU (50 μM) reduces the expression of α-SMA and Vimentin protein in primary mouse activated HSCs (Hepatic Stellate Cells).

28322315
Growth inhibition assay
Cell viability ; 

PubMed: 24956101     


CLL cells RPMI/0.1% FBS were cultured on 0.5% BSA or 150 nM MMP-9 for 1 h prior to adding the indicated concentrations of fludarabine (Fluda). After 48 h (Fluda) cell viability was determined by flow cytometry using FITC-Annexin V and PI.

24956101
In vivo Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • Concentrations: 2 μg/mL
  • Incubation Time: 24 hours
  • Method:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • Formulation: PBS
  • Dosages: 40 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL (suspension)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 285.23
Formula

C10H12FN5O4

CAS No. 21679-14-1
Storage powder
in solvent
Synonyms FaraA, Fludarabinum

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03832127 Not yet recruiting Drug: 18F-Fludarabine Myeloma Nantes University Hospital|Cyceron April 1 2019 Phase 1
NCT03348033 Enrolling by invitation Biological: Chronic Myeloid Leukemia + NK cell Chronic Myeloid Leukemia Hospital de Clinicas de Porto Alegre March 2019 Phase 1|Phase 2
NCT03613532 Recruiting Drug: Venetoclax|Drug: Fludarabine|Drug: Busulfan Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome (MDS)|Chronic Myelomonocytic Leukemia (CMML)|MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable)|Hematopoietic Stem Cell Transplant Jacqueline Garcia MD|Dana-Farber Cancer Institute October 1 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • Answer:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STAT Signaling Pathway Map

Related STAT Products

Tags: buy Fludarabine | Fludarabine supplier | purchase Fludarabine | Fludarabine cost | Fludarabine manufacturer | order Fludarabine | Fludarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID